OmniAb, Inc.

OABI ·Healthcare, Diagnostics & Research, United States
Financial Statements › Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021
Revenue $18.7M $26.4M $34.2M $59.1M $34.7M
Cost of Revenue — — — — —
Gross Profit — — — — —
Gross Margin — — — — —
Operating Expenses
Research & Development $47.8M $55.1M $56.5M $48.4M $39.2M
SG&A Expense $29.2M $30.7M $33.3M $24.9M $16.9M
Operating Income $-69.0M $-74.5M $-69.4M $-26.6M $-35.6M
Operating Margin -369.5% -282.3% -203.2% -45.1% -102.5%
Interest Expense — — — $0 $7.0K
Pretax Income $-66.3M $-71.4M $-64.4M $-26.1M $-34.4M
Income Tax Expense $-1.5M $-9.4M $-13.7M $-3.7M $-7.3M
Net Income $-64.8M $-62.0M $-50.6M $-22.3M $-27.0M
Net Margin -347.0% -235.1% -148.2% -37.8% -77.8%
EPS (Basic) $-0.57 $-0.61 $-0.51 $-0.26 $-0.33
EPS (Diluted) $-0.57 $-0.61 $-0.51 $-0.26 $-0.33
Shares Outstanding (Basic) 113.6M 102.4M 99.7M 85.3M 82.6M
Shares Outstanding (Diluted) 113.6M 102.4M 99.7M 85.3M 82.6M
Dividends Per Share — — — — —